EasySep™ Human CD34 Positive Selection Kit II

总览

使用EasySep™人CD34正选试剂盒 II，通过免疫磁珠正选可从新鲜或冻存的动员人外周血、骨髓单个核细胞 (MNCs)、冻存的脐带血MNCs、人胚胎干 (ES) 或诱导多能干 (iPS) 细胞中分离高纯度的CD34+细胞。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。

在此EasySep™正选过程中，目的细胞被识别CD34的抗体复合物和磁珠结合标记，抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。使用EasySep™磁极分离标记的目的细胞，通过简单倾倒即可去除非目标细胞，而目标细胞则保留在管中。磁珠分选后获得的人CD34+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD34抗原表达于造血干细胞和祖细胞表面。

该产品可替代EasySep™人CD34正选试剂盒 (产品号 #18056) 以进行更快的细胞分选。

如需从动员白细胞单采术样本中大规模分离人CD34+细胞，请选用大容量（1 x 10^10细胞）试剂盒（产品号 #100-1569）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别CD34的抗体复合物和磁珠结合标记，抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。使用EasySep™磁极分离标记的目的细胞，通过简单倾倒即可去除非目标细胞，而目标细胞则保留在管中。磁珠分选后获得的人CD34+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD34抗原表达于造血干细胞和祖细胞表面。

该产品可替代EasySep™人CD34正选试剂盒 (产品号 #18056) 以进行更快的细胞分选。

如需从动员白细胞单采术样本中大规模分离人CD34+细胞，请选用大容量（1 x 10^10细胞）试剂盒（产品号 #100-1569）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别CD34的抗体复合物和磁珠结合标记，抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。使用EasySep™磁极分离标记的目的细胞，通过简单倾倒即可去除非目标细胞，而目标细胞则保留在管中。磁珠分选后获得的人CD34+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD34抗原表达于造血干细胞和祖细胞表面。

该产品可替代EasySep™人CD34正选试剂盒 (产品号 #18056) 以进行更快的细胞分选。

如需从动员白细胞单采术样本中大规模分离人CD34+细胞，请选用大容量（1 x 10^10细胞）试剂盒（产品号 #100-1569）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别CD34的抗体复合物和磁珠结合标记，抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。使用EasySep™磁极分离标记的目的细胞，通过简单倾倒即可去除非目标细胞，而目标细胞则保留在管中。磁珠分选后获得的人CD34+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD34抗原表达于造血干细胞和祖细胞表面。

该产品可替代EasySep™人CD34正选试剂盒 (产品号 #18056) 以进行更快的细胞分选。

如需从动员白细胞单采术样本中大规模分离人CD34+细胞，请选用大容量（1 x 10^10细胞）试剂盒（产品号 #100-1569）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)

亚型
细胞分选试剂盒

细胞类型
造血干/祖细胞，多能干细胞

种属
人

样本来源
Bone Marrow，Cord Blood，其它细胞系，PBMC，多能干细胞，Whole Blood，Mobilized Leukopaks

筛选方法
Positive

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
嵌合体，免疫，干细胞生物学

查看更多显示更少

实验数据

Figure 1. Typical EasySep™ Human CD34 Positive Selection Kit II Isolation Profile

Starting with cord blood, mobilized peripheral blood or bone marrow MNCs, or ES and iPS cell cultures, the CD34+ cell content of the isolated fraction is typically 93.5 ± 1.1% (mean ± SD), using the purple EasySep™ Magnet. In the above example using frozen cord blood, the purities of the start and final isolated fractions are 2.2% and 94.7%, respectively.

Figure 2. FACS Data for Anti-Human CD34 Antibody, Clone 581, Alexa Fluor® 488-Conjugated

(A) Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD34 Antibody, Clone 581, Alexa Fluor® 488 (Catalog #60013AD) and Anti-Human CD45 Antibody, Clone HI30, APC (Catalog #60018AZ). (B) Flow cytometry analysis of PBMCs labeled with Mouse IgG1, kappa Isotype Control Antibody, Clone MOPC-21, Alexa Fluor® 488 (Catalog #60070AD), and Anti-Human CD45 Antibody, Clone HI30, APC. (C) Flow cytometry analysis of human PBMCs processed with the EasySep™ Human CD34 Positive Selection Kit (Catalog #17856) and labeled with Anti-Human CD34 Antibody, Clone 581, APC. Histograms show labeling of PBMCs (Start) and isolated cells (Isolated). Labeling of start cells with Mouse IgG1, kappa Isotype Control Antibody, Clone MOPC-21, Alexa Fluor® 488 is shown (solid line histogram).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

EasySep™ Human CD34 Positive Selection Kit II

Catalog #

100-1569

Lot #

All

Language

English

Document Type

Product Information Sheet

Product Name

EasySep™ Human CD34 Positive Selection Kit II

Catalog #

17856, 17856RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human CD34 Positive Selection Kit II

Catalog #

17856, 17856RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human CD34 Positive Selection Kit II

Catalog #

17856, 17856RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human CD34 Positive Selection Kit II

Catalog #

17856RF

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for Human Pluripotent Stem Cell Research

Reprogramming

Maintenance

Differentiation

Workflow Stages for Hematopoietic Stem and Progenitor Cell Research

Cell Sourcing and Isolation

Expansion and Differentiation

Analysis

Workflow Stages for Chimerism Analysis

Cell Isolation

Characterization

相关材料与文献

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial. R. Yen et al. Leukemia 2022 oct

Abstract

Despite the effectiveness of tyrosine kinase inhibitors (TKIs) against chronic myeloid leukemia (CML), they are not usually curative as some patients develop drug-resistance or are at risk of disease relapse when treatment is discontinued. Studies have demonstrated that primitive CML cells display unique miRNA profiles in response to TKI treatment. However, the utility of miRNAs in predicting treatment response is not yet conclusive. Here, we analyzed differentially expressed miRNAs in CD34+ CML cells pre- and post-nilotinib (NL) therapy from 58 patients enrolled in the Canadian sub-analysis of the ENESTxtnd phase IIIb clinical trial which correlated with sensitivity of CD34+ cells to NL treatment in in vitro colony-forming cell (CFC) assays. We performed Cox Proportional Hazard (CoxPH) analysis and applied machine learning algorithms to generate multivariate miRNA panels which can predict NL response at treatment-na{\{i}}ve or post-treatment time points. We demonstrated that a combination of miR-145 and miR-708 are effective predictors of NL response in treatment-na{\"{i}}ve patients whereas miR-150 and miR-185 were significant classifiers at 1-month and 3-month post-NL therapy. Interestingly incorporation of NL-CFC output in these panels enhanced predictive performance. Thus this novel predictive model may be developed into a prognostic tool for use in the clinic."

View publication

Enhancement of proliferation of human umbilical cord blood-derived CD34+ hematopoietic stem cells by a combination of hyper-interleukin-6 and small molecules. Y. S. Park et al. Biochemistry and biophysics reports 2022 mar

Abstract

Umbilical cord blood (UCB) is an alternative source of allogeneic hematopoietic stem cells (HSCs) for transplantation to treat various hematological disorders. The major limitation to the use of UCB-derived HSCs (UCB-HSCs) in transplantation, however, is the low numbers of HSCs in a unit of cord blood. To overcome this limitation, various cytokines or small molecules have been used to expand UCB-HSCs ex vivo. In this study, we investigated a synergistic effect of the combination of HIL-6, SR1, and UM171 on UCB-HSC culture and found that this combination resulted in the highest number of CD34+ cells. These results suggest that the combination of SR1, UM171 and HIL-6 exerts a synergistic effect in the proliferation of HSCs from UCB and thus, SR1, UM171 and HIL-6 is the most suitable combination for obtaining HSCs from UCB for clinical transplantation.

View publication

Asymmetric organelle inheritance predicts human blood stem cell fate. D. Loeffler et al. Blood 2022 mar

Abstract

Understanding human hematopoietic stem cell fate control is important for its improved therapeutic manipulation. Asymmetric cell division, the asymmetric inheritance of factors during division instructing future daughter cell fates, was recently described in mouse blood stem cells. In human blood stem cells, the possible existence of asymmetric cell division remained unclear because of technical challenges in its direct observation. Here, we use long-term quantitative single-cell imaging to show that lysosomes and active mitochondria are asymmetrically inherited in human blood stem cells and that their inheritance is a coordinated, nonrandom process. Furthermore, multiple additional organelles, including autophagosomes, mitophagosomes, autolysosomes, and recycling endosomes, show preferential asymmetric cosegregation with lysosomes. Importantly, asymmetric lysosomal inheritance predicts future asymmetric daughter cell-cycle length, differentiation, and stem cell marker expression, whereas asymmetric inheritance of active mitochondria correlates with daughter metabolic activity. Hence, human hematopoietic stem cell fates are regulated by asymmetric cell division, with both mechanistic evolutionary conservation and differences to the mouse system.

View publication

View All Publications

EasySep™人CD34正选试剂盒 II

产品号 #（选择产品）

产品号 #17856_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

种属	Human
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)
样本来源	Bone Marrow, Cord Blood, Mobilized Leukopaks, Other, PBMC, Pluripotent Stem Cells, Whole Blood
Selection Method	Positive

EasySep™人CD34正选试剂盒 II

产品号 #（选择产品）

产品号 #17856_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (13)

文献 (12)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台